tradingkey.logo

Xilio Therapeutics Announces Updated Phase 2 Data For Vilastobart, A Tumor-Activated Anti-Ctla-4, In Combination With Atezolizumab In Patients With Metastatic Microsatellite Stable Colorectal Cancer

ReutersMay 31, 2025 12:07 PM

- Xilio Therapeutics Inc XLO.O:

  • XILIO THERAPEUTICS ANNOUNCES UPDATED PHASE 2 DATA FOR VILASTOBART, A TUMOR-ACTIVATED ANTI-CTLA-4, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER

  • XILIO THERAPEUTICS INC - 26% RESPONSE RATE IN METASTATIC MSS CRC WITHOUT LIVER METASTASES

  • XILIO THERAPEUTICS INC - VILASTOBART AND ATEZOLIZUMAB SHOW WELL-TOLERATED SAFETY PROFILE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI